Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

Osteoarthritis, Hip Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03793010
• Other study ID #: FX006-2018-015
• Status: Terminated
• Phase: Phase 3
• Start date: December 12, 2018
• Est. completion date: August 7, 2019

Study information

• Verified date: January 2024
• Source: Pacira Pharmaceuticals, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a two-part, multi-center, randomized, double-blind, placebo-controlled, parallel-group study in patients with hip OA. Approximately 70 patients will be enrolled in Part I and approximately 440 patients will be enrolled in Part II of the study. In each part, patients will be randomized to one of two treatment groups (1:1) and treated with a single IA injection of either 32 mg FX006 or normal saline.

Description:

This is a two-part, multi-center, randomized, double-blind, placebo-controlled, parallel-group study in patients with hip OA. Approximately 70 patients will be enrolled in Part I and approximately 440 patients will be enrolled in Part II of the study. In each part, patients will be randomized to one of two treatment groups (1:1) and treated with a single IA injection of either 32 mg FX006 or normal saline.

FX006 or saline placebo will be administered as a single IA injection with a 12-week follow-up period in the double-blind phase.

Patients participating in Part I of the study will be treated with a single IA injection of either 32 mg FX006 or normal saline and will return for follow up visits at Weeks 12, 16, 20, and 24. The patients will be discontinued at the time of notification by the Investigator.

Patients participating in Part II of the study will be treated with a single IA injection of either 32 mg FX006 or normal saline and will return for follow up visits at Weeks 12, 16, 20, and 24.

Patients participating in Part II of the study that are not clinically indicated for a second injection at Week 12 will return to the clinic at Weeks 16, 20, and 24 and will receive an open-label injection of FX006 at the first evaluation where the patient has been determined to meet all criteria. Patients will then return for follow-up visits every 4 weeks for 12 weeks post second injection and will complete the study 12 weeks post second injection (e.g., Week 24, 28, 32, or 36 depending on when the patient receives the open-label injection).

Patients participating in Part II of the study who are not eligible for a second injection after evaluation at Weeks 12, 16, 20, and 24 will complete the study at the Week 24 visit and complete the End of Study (EOS) assessments.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 70
• Est. completion date: August 7, 2019
• Est. primary completion date: August 7, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions

• Patients 40 to 80 years of age, inclusive, on the day of randomization (Day 1)

• Body Mass Index (BMI) = 40 kg/m2

• Symptoms associated with OA of the index hip for = 3 months prior to Screening visit

• Currently meet the American College of Radiology (ACR) Criteria (clinical and radiological) for OA of the index hip

• Kellgren-Lawrence (KL) Grade 2 or 3 in the index hip as confirmed by X-ray during Screening visit (centrally read)

• Qualifying mean score on the WOMAC A and C (0-10 NRS scale)

• Agree to maintain the similar activity level throughout the study

• Willingness to abstain from use of restricted medications

Exclusion Criteria:

• Patients who cannot washout of prohibited medications

• Diagnosed as secondary OA in the index hip including but not limited to articular fracture, major dysplasia or congenital abnormality, osteochondritis dissecans, acromegaly, ochronosis, hemochromatosis, Wilson's disease, or primary osteochondromatosis, etc.

• Ipsilateral chronic knee pain

• Sciatica

• Atrophic osteoarthritis, femoral head necrosis and/or collapse, or subchondral bone insufficiency fracture in the index hip joint determined via central reading

• Current or history of infection in the index hip (e.g. osteomyelitis) or current skin infection at injection site

• Trauma or surgeries (e.g., arthroscopy, knee surgery) of lower limbs within 52 weeks with sequelae, etc.

• History or current evidence of reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease, systemic lupus erythematosus or other autoimmune diseases

• Any planned surgeries in the lower limbs during the study period, or any other surgery during the study period that would require use of a restricted medication

• Presence of surgical hardware or other foreign body in the index hip

• Planned/anticipated surgery of the index hip or any other surgery that would require use of a restricted medication during the study period

• IA corticosteroid of any joint within 3 months of Screening visit (investigational or marketed, including FX006)

• IA treatment of index hip with any of the following agents within 6 months of Screening: any biologic agent or hyaluronic acid (investigational or marketed)

• IV or IM corticosteroids (investigational or marketed) within 3 months of Screening

• Oral corticosteroids (investigational or marketed) within 1 month of Screening

• Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening visit

• Planned or expected changes to lifestyle with regard to physical activity, physical therapy, acupuncture, transcutaneous electrical nerve stimulation (TENS), or bracing within 1 month prior to Screening and changes throughout the duration of the study

• Women of child-bearing potential (not surgically sterile or post-menopausal for at least 1 year as documented in medical history) not using a highly effective method or who are pregnant or nursing

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis, Hip

Intervention

Drug:
• FX006
Single Intra-articular injection
• Normal saline
Single Intra-articular injection

Locations

Country	Name	City	State
United States	University Orthopedics Center	Altoona	Pennsylvania
United States	Northwest Clinical Research Center	Bellevue	Washington
United States	Injury Care Research, LLC	Boise	Idaho
United States	Hope Clinical Research	Canoga Park	California
United States	Clinical Trials of South Carolina	Charleston	South Carolina
United States	Coastal Carolina Research Center	Charleston	South Carolina
United States	Charlottesville Medical Research	Charlottesville	Virginia
United States	Northwestern University Feinberg School of Medicine	Chicago	Illinois
United States	Tampa Bay Medical Research	Clearwater	Florida
United States	Spectrum Medical, Inc.	Danville	Virginia
United States	Florida Research Associates, LLC	DeLand	Florida
United States	Mountain View Clinical Research, Inc.	Denver	Colorado
United States	Altoona Center for Clinical Research	Duncansville	Pennsylvania
United States	TriWest Research Associates, LLC	El Cajon	California
United States	Drug Trials America	Hartsdale	New York
United States	BioSolutions Clinical Research Center	La Mesa	California
United States	Excel Clinical Research	Las Vegas	Nevada
United States	Advanced Research for Health Improvement	Naples	Florida
United States	Medallion Clinical Research Institute, LLC	Naples	Florida
United States	Better Health Clinical Research, Inc	Newnan	Georgia
United States	Heartland Research Associates	Newton	Kansas
United States	Oviedo Medical Research	Oviedo	Florida
United States	Arizona Research Center	Phoenix	Arizona
United States	Progressive Medical Research	Port Orange	Florida
United States	M3 Wake Research, Inc.	Raleigh	North Carolina
United States	Wasatch Clinical Research, LLC	Salt Lake City	Utah
United States	Artemis Institute for Clinical Research	San Diego	California
United States	Precision Clinical Research, LLC	Sunrise	Florida
United States	Noble Clinical Research	Tucson	Arizona
United States	Chase Medical Research, LLC	Waterbury	Connecticut
United States	PMG Research of Wilmington	Wilmington	North Carolina
United States	National Pain Research Institute	Winter Park	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Pacira Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in WOMAC A (Pain) Score at Week 12	The change from baseline on the average Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A (pain) score at Week 12. The average WOMAC A score is calculated by taking the average of five questions with a range from 0 (no pain) to 10 (extreme pain).	Baseline and Week 12
Secondary	Change in WOMAC C (Function) Score at Week 12	Change from Baseline on the WOMAC C (function) score at Week 12. The average WOMAC C score is calculated by taking the average of seventeen questions with a range from 0 (no difficulty) to 10 (extreme difficulty).	Baseline and Week 12
Secondary	PGIC Score at Week 12	PGIC (Patient Global Impression of Change) at Week 12. The PGIC score has a range from 1(very much improved) to 7 (very much worse) and indicates the overall status of the patient since baseline.	12 Weeks